18F-DCFPyL PET/CT in Oncocytoma

Clin Nucl Med. 2018 Dec;43(12):921-924. doi: 10.1097/RLU.0000000000002301.

Abstract

A 76-year-old man with biochemical failure after primary radiotherapy for prostate cancer had no malignant disease detected on Tc-MDP bone scan and diagnostic CT. Prostate-specific membrane antigen (PSMA), a type II transmembrane glycoprotein, is overexpressed in prostate cancer cells. The PSMA-targeted F-DCFPyL PET/CT demonstrated lymph node disease and photopenic defects in the left kidney associated with a cyst and biopsy-proven oncocytoma. Prostate-specific membrane antigen is expressed in the neovasculature of several solid tumors. It has been reported that PSMA expression is seen in approximately 50% of oncocytoma versus 76% of clear cell renal carcinomas. Biopsy confirmation is needed regardless of F-DCFPyL avidity.

Publication types

  • Case Reports

MeSH terms

  • Adenoma, Oxyphilic / diagnostic imaging*
  • Aged
  • Humans
  • Kidney Neoplasms / diagnostic imaging*
  • Lysine / analogs & derivatives*
  • Male
  • Positron Emission Tomography Computed Tomography*
  • Radiopharmaceuticals*
  • Urea / analogs & derivatives*

Substances

  • 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
  • Radiopharmaceuticals
  • Urea
  • Lysine